Recent Advances in Transcription Factors Biomarkers and Targeted Therapies Focusing on Epithelial-Mesenchymal

Related Experiment Video

Updated: Jul 23, 2025

Induction and Analysis of Epithelial to Mesenchymal Transition
10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

35.8K

Kai-Ting Chuang1,2, Shyh-Shin Chiou3,4,5, Shih-Hsien Hsu1,5,6

  • 1Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.

Cancers
|July 14, 2023
PubMed

Insights

Transcription factors regulate gene expression and are crucial in epithelial-mesenchymal transition (EMT), a process driving cancer metastasis. Understanding these factors offers new therapeutic targets for cancer treatment.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Epigenetics

Background:

  • Transcription factors are proteins that control gene expression by binding to DNA.
  • Epithelial-mesenchymal transition (EMT) is a biological process implicated in cancer progression and metastasis.
  • Specific transcription factors, including Myc, SNAIs, Twists, and ZEBs, are known to drive EMT.

Purpose of the Study:

  • To review the oncogenic role of transcription factors in EMT.
  • To explore the involvement of transcription factors in epigenetic regulation during EMT.
  • To identify conserved transcription factor families in EMT for potential therapeutic targeting.

Main Methods:

  • Literature review of current evidence on transcription factors and EMT.
  • Analysis of studies focusing on EMT editing and epigenetic mechanisms.
  • Classification of relevant transcription factor families.

Main Results:

  • Dysregulated transcription factors are key drivers of tumor metastasis via EMT.
  • These factors play critical roles in regulating EMT and associated epigenetic changes.
  • Evidence highlights conserved transcription factor families involved in EMT.

Conclusions:

  • Transcription factors are pivotal in regulating EMT and cancer progression.
  • Targeting specific transcription factors involved in EMT presents a promising therapeutic strategy.
  • Further research into these factors can advance cancer treatment.
Keywords:
cancer targeted therapyepithelial–mesenchymal transitiontranscription factor

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.5K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.1K

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K